Celiac disease (CD) is an autoimmune enteropathy characterized by gluten-triggered intestinal mucosa lesions in genetically susceptible individuals carrying the HLA DQ2 or DQ8. CD diagnosis is based on the concentration of IgA serum antitransglutaminase (anti-tTG) antibodies together with mucosal damage at intestinal biopsy.
with both normal mucosa and serum anti-tTG, were analysed by phage display technology. All patients diagnosed as having CD markers were followed for their clinical condition, the concentration of serum anti-tTGs and the effects of a 24-month GFD or GCD.
Serum IgA anti-TG antibodies were measured using an ELISA assay (Eurospital, Trieste, Italy) following the manufacturer's instructions (n.v.,7 U/ml). Serum IgA anti-endomysium antibodies (AEAs), HLA DQ2/8 alleles and phage IgA anti-tTG antibody libraries were evaluated as previously described. 3 The histological classification of the intestinal biopsies was based on Oberhuber's criteria. 5 The frozen sections were examined for the IgA anti-tTG deposits by direct double immunofluorescence as previously described.
2 Briefly, the sections were incubated with a monoclonal mouse antibody against transglutaminase type-2 enzyme (CUB7402; NeoMarkers, Fremont, California, USA) to detect (in red) the transglutaminase enzyme and by fluorescein anti-human IgA rabbit antibody (Dako, Glostrup, Denmark) to detect (in green) IgA deposits. The multicolour analysis was performed by Axioplan2 Zeiss fluorescence microscope to localize in yellow colour the IgA anti-tTG.
To elute IgA anti-tTG from intestine specimens, the biopsies were cut into fragments in 0.2 M glycine solution (pH 2.2), sonicated on ice and neutralized with 1 M Tris-HCl (pH 9.1). Protein concentration was measured by the Bradford's method and 50 mg of protein were incubated with tosylactivated M-280 Dynabeads coupled with human recombinant tissue transglutaminase type 2. The beads were washed with phosphate-buffered saline (PBS) Tween 0.3% and incubated with fluorescein conjugated anti-human IgA. By flow cytometry, we measured the percentage of fluorescent beads in a total count of 10 000 4 These two authors contributed equally to the study. 1 beads and we selected a cutoff value based on the receiver-operating characteristic curve (ROC) at 14.5% of fluorescence.
Informed consent was obtained from the parents of 135 children and from 15 young adults (81 female, 69 male, median age: 11 years). Seventy-two patients (48%) were suspected of having CD because they suffered from symptoms as abdominal distension, sideropenic anemia, diarrhea, and were positive for both IgA anti-tTG, AEA, and for the presence of HLA-DQ2/DQ8. The intestinal biopsies from these 72 patients showed villous atrophy and they were diagnosed with CD, putted on GFD and followed for 24 months. The remaining 78 patients (52%) underwent gastrointestinal endoscopy for recurrent abdominal pain, anemia and failure to thrive, but they were negative for the serum antitTG and 21/78 (27%) carry the HLA-DQ2. No villous atrophy was observed in these 78 cases. All patients had normal concentration of total IgA (163649 mg/dl).
The 72 celiacs were positive for both immunoassays (sensitivity: 100%). In the remaining 78 patients, negative for serum anti-tTG and with normal intestine, eight (positive for HLA-DQ2) were positive for both immunoassays, two (positive for HLA-DQ2) showed intestinal anti-tTG deposits only and two (negative for HLA DQ2/8) were positive to flow cytometry assay alone (Figure 1 ).
Nine out of 10 HLA-DQ2 patients' biopsies were positive for phage display antibody technology. These nine patients were considered at risk of CD, and the GFD was proposed to three of them who were suffering from anemia; the remaining seven patients continued the GCD (Table 1) .
After GFD, the 72 CD patients improved (serum IgA antitTG concentrations before and after GFD 97669 U/ml vs. 5.962.1 U/ml, P,0.0001). The three patients at risk of CD with anemia ameliorated, while after GCD, two patients presented high titers of serum anti-tTG and positive AEA and four patients remained negative to the serum anti-tTG (Table 1) .
The measurement of intestinal anti-tTG deposits by our two immune techniques demonstrated a 100% sensitivity in agreement to current CD diagnostic criteria, while they demonstrated a low specificity (87%) because they identified symptomatic patients without the CD-diagnostic criteria. Moreover, they clinically improved in the course of GFD and isolating by phage display assay the intestinal anti-tTG from these patients, we found a specific gluten-dependent autoimmune response similar to that seen in untreated biopsyproven patients. Particularly the anti-tTG antibody repertoire was dominated by usage of VH5-51 gene segment, and in the remaining cases by the VH1 (3/9) and by the VH3 (1/9) gene segments, as found by Di Niro and co-workers 6 using singlecell PCR on intestinal B lymphocytes of biopsy-proven CD patients. In this study, the V region primer was designed to amplify specifically VH5-51 gene segment, but is possible the amplification of VH1 and VH3 family members due to the high sequence homology with other VH families. Altogether, our data indicate that the presence of mucosal anti-tTG represents an early stage of the celiac immunological response, and that clinical signs such as anemia are reversible with GFD. In CD, the anti-tTG might exert an adverse biological effects as proved by in vivo human studies involving intestine, skin, 7 placenta 8 and brain, 9 and by the accompanying organ-specific symptoms which disappeared during the GFD. Recently, it was observed that pregnant women bearing the HLA-DQ2 have significantly impaired fetal growth development, in the presence of serum anti-tTG concentrations exceeding the diagnostic cutoff limit (.6 U/ml), but also with an intermediate serum anti-tTG antibody concentration (from 0.8 to ,6 U/ml) in comparison to pregnant women with lower intermediate anti-tTG values. In the context of genetic gluten intolerance, mothers with intermediate serum anti-tTG concentration may have subclinical CD, becoming future patients with overt CD and that these antibodies may play a role in fetal growth restriction. 10 This study poses an important issue regarding the early diagnosis of gluten genetic intolerance in absence of intestinal damage and/ or abnormal serum anti-tTG concentrations and whether GFD may be used to treat these patients.
In our opinion, searching for intestinal anti-tTG may help the physician to recognize those patients who do not fulfill the CD diagnostic criteria and more importantly, to treat glutendependent symptoms such as anemia.
